BACKGROUND: Over the last decade of years, minimally invasive techniques have been developed for the treatment of hepatocellular carcinoma and liver metastases. We sought to investigate the health costs associated with the management of patients with hepatocellular carcinoma treated with radiofrequency vs laser thermal ablation and their clinical outcomes. METHODS: We performed a retrospective analysis of the ablations performed in two referral centers in southern Italy, from 2009 to 2013. Resource use was valued by year 2017 official prices, in (sic). Direct healthcare costs (drugs, visits, tests and hospitalizations) of different ablation techniques were compared. Total costs were analyzed from Italian NHS perspective. RESULTS: A total of 140 patients were identified. Baseline demographics and clinical outcomes of interest did not differ between the two groups. Patients treated with laser thermal ablation resulted in an expected annually cost savings of 258.9 (sic) per patient, in one-year follow-up healthcare costs compared with radiofrequency. The largest components of annual medical expenditures were attributable to drugs, regardless of the type of ablative technique. CONCLUSIONS: The ablation using either laser thermal ablation or radiofrequencv is equally effective. Laser thermal ablation would cam disposable cost savings as compared to radiofrequency. The costs associated with management of patients with hepatocellular carcinoma, treated with laser thermal ablation were lower than those treated with radiofrequency ablation.

Cost Minimization Analysis of Radiofrequency Compared to Laser Thermal Ablation in Patients with Hepatocellular Carcinoma / Guarino, Maria; D'Angiolella, Lucia Sara; Falco, Luigia; Morando, Federica; Di Costanzo, Giovan Giuseppe; Morisco, Filomena; Improta, Giovanni; Mantovani, Lorenzo Giovanni; Caporaso, Nicola. - In: FARMECONOMIA E PERCORSI TERAPEUTICI. - ISSN 2240-256X. - 20:1(2019), pp. 43-50. [10.7175/fe.v20i1.1401]

Cost Minimization Analysis of Radiofrequency Compared to Laser Thermal Ablation in Patients with Hepatocellular Carcinoma

D'Angiolella, Lucia Sara;Falco, Luigia;Morando, Federica;Morisco, Filomena;Improta, Giovanni;Mantovani, Lorenzo Giovanni;
2019

Abstract

BACKGROUND: Over the last decade of years, minimally invasive techniques have been developed for the treatment of hepatocellular carcinoma and liver metastases. We sought to investigate the health costs associated with the management of patients with hepatocellular carcinoma treated with radiofrequency vs laser thermal ablation and their clinical outcomes. METHODS: We performed a retrospective analysis of the ablations performed in two referral centers in southern Italy, from 2009 to 2013. Resource use was valued by year 2017 official prices, in (sic). Direct healthcare costs (drugs, visits, tests and hospitalizations) of different ablation techniques were compared. Total costs were analyzed from Italian NHS perspective. RESULTS: A total of 140 patients were identified. Baseline demographics and clinical outcomes of interest did not differ between the two groups. Patients treated with laser thermal ablation resulted in an expected annually cost savings of 258.9 (sic) per patient, in one-year follow-up healthcare costs compared with radiofrequency. The largest components of annual medical expenditures were attributable to drugs, regardless of the type of ablative technique. CONCLUSIONS: The ablation using either laser thermal ablation or radiofrequencv is equally effective. Laser thermal ablation would cam disposable cost savings as compared to radiofrequency. The costs associated with management of patients with hepatocellular carcinoma, treated with laser thermal ablation were lower than those treated with radiofrequency ablation.
2019
Cost Minimization Analysis of Radiofrequency Compared to Laser Thermal Ablation in Patients with Hepatocellular Carcinoma / Guarino, Maria; D'Angiolella, Lucia Sara; Falco, Luigia; Morando, Federica; Di Costanzo, Giovan Giuseppe; Morisco, Filomena; Improta, Giovanni; Mantovani, Lorenzo Giovanni; Caporaso, Nicola. - In: FARMECONOMIA E PERCORSI TERAPEUTICI. - ISSN 2240-256X. - 20:1(2019), pp. 43-50. [10.7175/fe.v20i1.1401]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/779122
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact